Adagene Stock
Adagene Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- CEO
- Peter Luo
- Employees
- 128
- Market cap
- $78 M
- IPO
- 09/02/2021
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets…
Adagene stock: price history
1D
-14.2%
1W
-25.4%
1M
-35.0%
6M
-48.1%
YTD
+9.0%
1Y
+15.7%
2Y
-13.8%
5Y
-82.4%
10Y
–
Next earnings date
Next earnings date
31/03/2027 (in 165 days)
Volatility around earnings
~13% stronger price swings than usual
Ask the agents about Adagene
Analyst assessment of Adagene
PRICE TARGET LOW
US$7.00
CONSENSUS
US$8.67
MEDIAN
US$9.00
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 14/09/2026
Adagene stock metrics
P/E
-4.37
P/B
0.88
EV/EBITDA
2.03
RETURN ON EQUITY
-15.5%
NET MARGIN
-1,011.1%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.7%
FLOAT SHARES
26,986,225
AVG. DAILY VOLUME (30D)
346,646
Insider transactions (SEC)
Tam Man Kin
Luo Peter
DO CUONG V
Luo Peter
Luo Peter
Institutional holders
Comparable stocks
Frequently asked questions about Adagene stock
What does Adagene do?
Adagene Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in China.
The CEO is Peter Luo, the company employs around 128 people.
The IPO was on 09/02/2021; the stock trades on NASDAQ under the ticker ADAG.
What do analysts say about Adagene stock?
5 analysts rate the stock, the consensus is Buy (as of 14/09/2026).
The average price target is US$8.67, ranging from US$7.00 to US$10.00, with a median of US$9.00.
This is an external assessment, not a statement by Market Jury.
When does Adagene report next?
The next earnings date is 31/03/2027.
Around past earnings, price swings were roughly 13% stronger than usual.
Does Adagene pay a dividend?
No, Adagene currently does not pay a dividend.
Which stocks are comparable to Adagene?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Adagene stock analyzed?
Clicking "Analyze stock" lets five strategies assess Adagene against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.